Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer.
Suzuki M, Takenaka Y, Kishikawa T, Yamamoto Y, Hanamoto A, Tomiyama Y, Fukusumi T, Michiba T, Takemoto N, Nakahara S, Inohara H.
Suzuki M, et al. Among authors: tomiyama y.
Anticancer Res. 2021 Apr;41(4):2045-2051. doi: 10.21873/anticanres.14973.
Anticancer Res. 2021.
PMID: 33813412